# Advances and applications of organ-on-a-chip technology

**Authors:** Jeong Sik Kong, Jisoo Kim, Jinah Jang, Dong-Woo Cho

PMC · DOI: 10.1016/j.crmeth.2026.101361 · Cell Reports Methods · 2026-03-23

## TL;DR

This review explores how organ-on-a-chip technology mimics human organs for better drug testing and disease modeling.

## Contribution

The paper provides a comprehensive overview of fabrication methods and diverse applications of organ-on-a-chip systems.

## Key findings

- OOC systems offer more accurate alternatives to traditional testing methods by simulating human organ conditions.
- Applications include disease modeling, drug testing, and personalized medicine.
- OOCs are being used in space research to study microgravity and radiation effects on human health.

## Abstract

Advancements of the organ-on-a-chip (OOC) technology have been at the forefront of multidisciplinary convergence, blending biology, engineering, and microfabrication. OOC systems recreate human organ functionalities on microfluidic devices and offer more accurate alternatives to traditional testing methods. In this review, we discuss the various fabrication methods such as microfluidics, bioprinting, and injection molding, which are vital for the development of this technology. We further highlight the capability of OOC devices to accurately simulate human organ conditions and their applications in disease modeling, drug testing, and personalized medicine. The integration of OOCs in biological research, including as biosensors for real-time monitoring and in disease modeling, and the use of OOC systems in space research, particularly for studying the effects of microgravity and radiation on human health aboard the International Space Station, are also discussed. This technology shows immense promise for transforming approaches in drug discovery, toxicology, and personalized medicine.

Organ-on-a-chip technology recreates key structural and functional features of human organs within microfluidic platforms, providing physiologically relevant alternatives to conventional models. In this review, Kong et al. summarize the various fabrication and cultivation strategies and discuss their applications ranging from biosensors, drug testing, and disease modeling to space biology.

## Full-text entities

- **Genes:** ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, LAMB2 (laminin subunit beta 2) [NCBI Gene 3913] {aka LAMS, NPHS5, PIERS}, CDH5 (cadherin 5) [NCBI Gene 1003] {aka 7B4, CD144}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CLDN5 (claudin 5) [NCBI Gene 7122] {aka AWAL, BEC1, CPETRL1, TMDVCF, TMVCF}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, TFRC (transferrin receptor) [NCBI Gene 7037] {aka CD71, IMD46, T9, TFR, TFR1, TR}
- **Diseases:** hepatotoxic compounds (MESH:D005597), pulmonary leakage (MESH:D003763), IBD (MESH:D015212), lung cancer (MESH:D008175), kidney damage (MESH:D007674), Obesity (MESH:D009765), type 2 diabetes (MESH:D003924), metastasis (MESH:D009362), Parkinson disease (MESH:D010300), gastric cancer (MESH:D013274), muscle wastage (MESH:D009133), OOC (MESH:D000092124), toxicity (MESH:D064420), drug (MESH:D000081015), MPSs (MESH:D015619), neurodegenerative diseases (MESH:D019636), GI disease (MESH:D005767), DILI (MESH:D056486), Cancer (MESH:D009369), glioblastoma (MESH:D005909), pulmonary edema (MESH:D011654), hyperglycemia (MESH:D006943), breast cancer (MESH:D001943), cardiotoxic (MESH:D066126), colon adenocarcinoma (MESH:D003110), inflammation (MESH:D007249), edema (MESH:D004487)
- **Chemicals:** AA (-), polymers (MESH:D011108), poly(N-isopropylacrylamide (MESH:C052970), PDMS (MESH:C013830), lactate (MESH:D019344), polystyrene (MESH:D011137), PCL (MESH:C016240), PVA (MESH:D011142), Oxygen (MESH:D010100), nicotine (MESH:D009538), cisplatin (MESH:D002945), iodixanol (MESH:C044834), inulin (MESH:D007444), empagliflozin (MESH:C570240), hyaluronic acid (MESH:D006820), uric acid (MESH:D014527), Styrene (MESH:D020058), PMMA (MESH:D019904), creatinine (MESH:D003404), PEG (MESH:D011092), FITC-dextran (MESH:C015219), quartz (MESH:D011791), glycosaminoglycans (MESH:D006025), ATP (MESH:D000255), CO2 (MESH:D002245), GSK2193874 (MESH:C000628859), glucose (MESH:D005947), urea (MESH:D014508), water (MESH:D014867), polyacrylamide (MESH:C016679), cyclosporine (MESH:D016572), short-chain fatty acids (MESH:D005232)
- **Species:** Homo sapiens (human, species) [taxon 9606], Hepatitis B virus (no rank) [taxon 10407]
- **Cell lines:** HBMEC — Homo sapiens (Human), Transformed cell line (CVCL_0307), Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025), HUVEC — Homo sapiens (Human), Finite cell line (CVCL_2959)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13030988/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13030988/full.md

## References

225 references — full list in the complete paper: https://tomesphere.com/paper/PMC13030988/full.md

---
Source: https://tomesphere.com/paper/PMC13030988